FLUOCINOLONE ACETONIDE IMPLANT IN THE TREATMENT OF RETINAL ANGIOPATHY MACULAR EDEMA IN ATTRV30M PATIENTS.

Abstract

To evaluate the effectiveness and safety of the fluocinolone acetonide implant (0.2 µ g/day fluocinolone acetonide, ILUVIEN) in macular edema due to retinal amyloid angiopathy in patients with hereditary transthyretin amyloidosis associated with the V30M mutation (ATTRV30M). Retrospective observational case series of ATTRV30M patients' eyes treated with the implant for macular edema, from January 2010 to December 2019. Best-corrected visual acuity, central foveal thickness, and intraocular pressure were measured at baseline, at 1 week, and at months 1, 3, 6, and 12. Fifteen eyes of 15 ATTRV30M patients with fluocinolone acetonide implants were included. All patients had already received a liver transplant. All had already been submitted to cataract surgery: 87% had an Ahmed valve implant, and 80% were vitrectomized due to vitreous amyloidosis. A statistically significant improvement in best-corrected visual acuity and in central foveal thickness at all time points was found compared with baseline. There was no statistically significant difference in intraocular pressure during the follow-up. Patients with macular edema due to retinal amyloid angiopathy treated with the fluocinolone acetonide implant showed sustained increased functional results and anatomical improvement compared with baseline.